In conclusion, by blocking the PI3K/AKT/mTOR pathway, SchC successfully repaired the autophagy damage in the mouse liver, opening up a new therapeutic avenue for the management of associated liver disorders. This evidence concerns the gene AKT1 and liver disorder.